Popular Articles

Seasonal Flu Vaccine Unlikely To Protect Against New H1N1 Says CDC
According to the US Centers for Disease Control and Prevention (CDC), vaccination with seasonal flu vaccines made for the 2005 to 2009
diet pills
ActoGeniX Obtains IND Approval
ActoGeniX, a development stage biopharmaceutical company, announced that the United States÷´ Food and Drug Administration (FDA) has approved the Company÷´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX÷´s portfolio.
News of the day
Stem Cell Surprise For Tissue Regeneration
Scientists working at the Carnegie Institution"s Department of Embryology, with colleagues, have overturned previous research that identified critical genes for making muscle stem cells. It turns out that the genes that make muscle stem cells in the embryo are surprisingly not needed in adult muscle stem cells to regenerate muscles after injury. The finding challenges the current course of research into muscular dystrophy, muscle injury, and regenerative medicine, which uses stem cells for healing tissues, and it favours using age-matched stem cells for therapy. The study is published in the June 25 advance on-line edition of Nature.
Cardiovascular

Future Of Independent Sector Treatment Centres, UK

The future use of Independent Sector Treatment Centres (ISTCs) in the NHS, will be fairer and on the same terms as other providers of NHS services, Health Minister Mike O"Brien announced today. Under the changes set out today, each contract will be reviewed on a case-by-case basis and new services will be commissioned by the local Primary Care Trust where they are designed to meet local needs, provide value for money and benefit patients in that community. Primary Care Trusts are already responsible for procuring a broad range of services from NHS and independent sector providers on behalf of local patients. In future, contracts to provide services from these treatment centres will also be paid under the same pricing arrangements as NHS providers. Services will be delivered under the terms and conditions of the standard NHS national contract for acute hospital services - the same contract used by NHS providers. Where the NHS identifies an ongoing need for services, there will be a competitive tendering process and bidders, including those from the independent sector, will be invited to deliver services at NHS tariff prices. Health Minister, Mike O"Brien said: "We need providers of NHS services, to deliver safe and high quality care for patients and value for money, but there should also be consistency in pricing and contracts. In the past the Independent Sector have sometimes been guaranteed payments. In the future it is intended that contracts will operate at NHS tariff prices using the standard NHS contract for hospital services. "Where independent sector providers offer value for money, innovation and high quality patient care, they have a role to play within the NHS. Independent Sector Treatment Centres have helped patients by increasing choice and capacity, and reducing waiting times. "Greater local control and day-to-day management will ensure these services are better integrated in to the local health system and reflect local needs." The changes will take effect in the second wave of ISTC contracts, the first of which will be advertised in August 2009. The first wave of contracts are due to end from 2010. Both independent sector and NHS providers will be eligible to bid for the new contracts, which will be commissioned locally by the NHS, rather than by the Department of Health. Independent Sector Treatment Centres (ISTCs) have helped improve health services for patients, reduce waiting times and improve patient choice in the NHS. More than 1.7 million operations, diagnostic assessments and primary care consultations have been provided to NHS patients at ISTCs. ISTCs have pioneered innovative approaches that have delivered improvements for patients in access to services and quality of care, such as fixed site treatment centres typically specialising in a range of elective procedures and mobile diagnostic services to NHS patients in locations close to their home. Department of Health, UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):